| Expression pattern: |
UP |
| Associated gene: |
IL6ST / Il6st, AGO2, IL-17A |
| Associated microRNA: |
miR-378a-3p |
| Biological function: |
circPHF16 promotes IL-17A expression and secretion by T lymphocytes/Jurkat cells and contributes to the immunopathological mechanism of Graves' disease. |
| Molecular mechanism: |
circPHF16 acts as a ceRNA/sponge for miR-378a-3p, thereby positively regulating IL6ST expression and promoting IL-17A expression and secretion; bioinformatic analysis implicated the JAK-STAT pathway. |
| Biological pathway or process: |
ceRNA regulation (promotes); JAK/STAT (promotes); immune regulation (promotes); inflammation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; ELISA; In Vivo Animal Model; H&E Staining; Bioinformatics Analysis |
| Clinical significance: |
circPHF16 is identified as a potential target for new approaches to Graves' disease diagnosis and treatment. |
| Description: |
circPHF16 is up-regulated in PBMCs and serum of Graves' disease patients and in splenic CD4+ T lymphocytes of GD model mice. It promotes IL-17A expression and secretion in Jurkat T cells by acting as a ceRNA that sequesters miR-378a-3p and up-regulates IL6ST, with predicted involvement of the JAK-STAT pathway. The study proposes circPHF16 as a potential diagnostic and therapeutic target for GD. |
| Confidence score: |
0.8324 |